Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer

Locoregional recurrence of differentiated thyroid cancer (DTC) occurs in 20% of thyroid cancer patients. Currently, there are many strategies for management of locoregional recurrence of DTC that lead to local control of the disease. The introduction of lenvatinib into the therapeutic armamentarium...

Descripción completa

Detalles Bibliográficos
Autor principal: Berciano‐Guerrero, Miguel‐Ángel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537059/
https://www.ncbi.nlm.nih.gov/pubmed/36202609
http://dx.doi.org/10.1002/cam4.5108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537059/
https://www.ncbi.nlm.nih.gov/pubmed/36202609
http://dx.doi.org/10.1002/cam4.5108

Ejemplares similares